Trevor D. Schuler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Trevor D. Schuler has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Shubha De
Department of Urology, University of Alberta, Edmonton, Alberta, Canada
2 shared publications - Anne R. Buckley
Department of Radiology, University of British Columbia, Stone Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
1 shared publication - Ben Hall Chew
Department of Urology University of British Columbia Vancouver Canada
1 shared publication - Callum Lavoie
Division of Urology, Children's Hospital Los Angeles, Los Angeles, CA, USA
1 shared publication - Connor Martin Forbes
University of British Columbia
1 shared publication Conrad Bayley
University of Alberta, Faculty of Medicine and Dentistry
1 shared publication
Latest Publications
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (4) , 580-589
Break Wave Lithotripsy for Urolithiasis: Results of the First-in-Human International Multi-Institutional Clinical Trial
This study reports on a prospective, multicenter, single-arm, clinical trial utilizing the SonoMotion (San Mateo, California) Break Wave lithotripsy (BWL) device to fragment urinary stones. Patients with a urinary stone underwent a single treatment of 30 minutes and peak negative pressure of 4.5 to 8 MPa. Subjects were contacted and outcomes assessed at 7, 14, and 35 days after treatment, with clinical follow-up and CT imaging 70 ± 14 days postprocedure. The primary objectives were to assess the safety (hematomas, complications, etc) and effectiveness of BWL (any fragmentation, residual fragments ≤4 mm or ≤2 mm, and completely stone-free rate) as assessed via noncontrast CT-kidneys, ureters, and bladder. Forty-four patients with a ureteral (43%) or renal (57%) stone were treated across 5 centers. Stone fragmentation occurred in 88% of cases; 70% had fragments ≤ 4 and 51% ≤ 2 mm, while 49% were completely stone free on CT; no serious adverse events were reported. Eighty-six percent of patients received either no analgesic medication at all (50%) or minor analgesia (36%). After determining optimal therapy settings, 36 patients were treated and the effectiveness improved exhibiting fragmentation in 92% (33/36), residual fragments ≤ 4 mm in 75% and 58% with fragments ≤ 2 mm with 58% completely stone free. Effectiveness was less in subjects with lower pole stones with 81% fragmentation, 71% having fragments ≤ 4 mm, 29% with fragments ≤ 2 mm, and 29% completely stone free; of distal ureteral stone patients, 89% were completely stone free. BWL offered safe and effective noninvasive stone therapy requiring little to no anesthesia and was carried out successfully in nonoperative environments. ClinicalTrials.gov identifier: NCT03811171.
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (4) , 580-589
Open AccessBreak Wave Lithotripsy for Urolithiasis: Results of the First-in-Human International Multi-Institutional Clinical Trial
This study reports on a prospective, multicenter, single-arm, clinical trial utilizing the SonoMotion (San Mateo, California) Break Wave lithotripsy (BWL) device to fragment urinary stones. Patients with a urinary stone underwent a single treatment of 30 minutes and peak negative pressure of 4.5 to 8 MPa. Subjects were contacted and outcomes assessed at 7, 14, and 35 days after treatment, with clinical follow-up and CT imaging 70 ± 14 days postprocedure. The primary objectives were to assess the safety (hematomas, complications, etc) and effectiveness of BWL (any fragmentation, residual fragments ≤4 mm or ≤2 mm, and completely stone-free rate) as assessed via noncontrast CT-kidneys, ureters, and bladder. Forty-four patients with a ureteral (43%) or renal (57%) stone were treated across 5 centers. Stone fragmentation occurred in 88% of cases; 70% had fragments ≤ 4 and 51% ≤ 2 mm, while 49% were completely stone free on CT; no serious adverse events were reported. Eighty-six percent of patients received either no analgesic medication at all (50%) or minor analgesia (36%). After determining optimal therapy settings, 36 patients were treated and the effectiveness improved exhibiting fragmentation in 92% (33/36), residual fragments ≤ 4 mm in 75% and 58% with fragments ≤ 2 mm with 58% completely stone free. Effectiveness was less in subjects with lower pole stones with 81% fragmentation, 71% having fragments ≤ 4 mm, 29% with fragments ≤ 2 mm, and 29% completely stone free; of distal ureteral stone patients, 89% were completely stone free. BWL offered safe and effective noninvasive stone therapy requiring little to no anesthesia and was carried out successfully in nonoperative environments. ClinicalTrials.gov identifier: NCT03811171.
- 10 June 2024
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 18 (10) , 310-315
Are renal stone protocol computed tomography reports giving us enough information?
Introduction: Non-contrast computed tomography (CT) is the gold-standard diagnostic test for urolithiasis. Little is published regarding which information needs to be included in the report for it to be most useful to the healthcare team for efficient triage and high-quality patient care. This study aimed to assess the quality and variability of CT scan reporting at a single Canadian tertiary academic medical center. Methods: We completed a retrospective review of 100 consecutive renal colic CT scans. Descriptive statistics were used to report the frequency with which specific elements commonly used by urologists to triage and treat patients were included in radiology reports. Results: Our sample had a mean age of 51.4±13.1 years. Stone size was universally reported for obstructing stones but was less frequently reported for non-obstructing stones (100% vs. 86.8%). A similar trend was observed for the exact stone number (100% vs. 93.4%). Non-obstructing stones were more likely than obstructing stones to be reported in one dimension (77.5% vs. 47%). Obstructing stones were reported in three dimensions 27% of the time. CT reports commonly include the presence or absence of hydronephrosis status (98%) but are less likely to include renal size (32%) and periureteral stranding (16%). Hounsfield units (HU) were reported in 3% of the reports, but skin-to-stone distance (SSD) and radiation dose were never reported. Conclusions: Reports routinely included assessments of stone size, location, and number (although not uniformly). HU, SSD, and radiation dose were rarely reported. This provides insight into opportunities for standardized reporting to optimize knowledge transfer that may result in clinical efficiency and improved quality of patient care.
- 10 June 2024
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 18 (10) , 310-315
Are renal stone protocol computed tomography reports giving us enough information?
Introduction: Non-contrast computed tomography (CT) is the gold-standard diagnostic test for urolithiasis. Little is published regarding which information needs to be included in the report for it to be most useful to the healthcare team for efficient triage and high-quality patient care. This study aimed to assess the quality and variability of CT scan reporting at a single Canadian tertiary academic medical center. Methods: We completed a retrospective review of 100 consecutive renal colic CT scans. Descriptive statistics were used to report the frequency with which specific elements commonly used by urologists to triage and treat patients were included in radiology reports. Results: Our sample had a mean age of 51.4±13.1 years. Stone size was universally reported for obstructing stones but was less frequently reported for non-obstructing stones (100% vs. 86.8%). A similar trend was observed for the exact stone number (100% vs. 93.4%). Non-obstructing stones were more likely than obstructing stones to be reported in one dimension (77.5% vs. 47%). Obstructing stones were reported in three dimensions 27% of the time. CT reports commonly include the presence or absence of hydronephrosis status (98%) but are less likely to include renal size (32%) and periureteral stranding (16%). Hounsfield units (HU) were reported in 3% of the reports, but skin-to-stone distance (SSD) and radiation dose were never reported. Conclusions: Reports routinely included assessments of stone size, location, and number (although not uniformly). HU, SSD, and radiation dose were rarely reported. This provides insight into opportunities for standardized reporting to optimize knowledge transfer that may result in clinical efficiency and improved quality of patient care.
- Open Access
- 10 June 2022
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 9 (2) , 98-102
Repeat Imaging to Avoid Surgery: An Initiative to Reduce-Negative Ureteroscopy in Patients with Ureteral Stones
- 10 June 2022
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 9 (2) , 98-102
Open AccessRepeat Imaging to Avoid Surgery: An Initiative to Reduce-Negative Ureteroscopy in Patients with Ureteral Stones
- 1 March 2009
- Published by SAGE Publications in Journal of Endourology
- Vol. 23 (3) , 387-393
Medical Expulsive Therapy as an Adjunct to Improve Shockwave Lithotripsy Outcomes: A Systematic Review and Meta-Analysis
Modern shockwave lithotripsy (SWL) is associated with inferior results compared with the original Dornier HM3. To enhance SWL outcomes, improved patient selection based on radiographic features and modulation of shockwave delivery rate have been used. A growing body of evidence demonstrates the positive effect of medical expulsive therapy (MET) to improve spontaneous passage of urinary calculi. The purpose of this review is to tabulate the current available data that examine the addition of MET to SWL to enhance outcomes. MEDLINE was searched with a strategy developed in conjunction with a medical librarian. Trials were included if patients were randomized to receive either a medical expulsive agent or placebo or standard therapy after SWL. Study quality was assessed according to the Cochrane Renal Group criteria. The data were analyzed using RevMan meta-analysis software. Subgroup analysis was performed with respect to MET agent used, stone size, and duration of follow-up. Four randomized trials were identified. MET agents varied, with two trials using tamsulosin, one using nifedipine, and a single trial using Phyllanthus niruri extract. Two trials included patients with renal calculi, one had patients with ureteral calculi, and the fourth included patients with both ureteral and renal calculi. The pool results of the four trials included 212 patients who received MET and 206 who received placebo. The absolute risk difference of a successful outcome after SWL with the addition of MET was significantly superior to control at 17% (95% confidence interval [CI] 9%-24%); means six patients need to be treated with MET to prevent a single unsuccessful SWL of six (95% CI 4-11). The effect of MET post-SWL was even more pronounced for stones larger than 10 mm with an absolute risk difference of 26% (95% CI, 9%-43%). MET post-SWL results in a significant increase in successful treatment outcomes. Further powered, randomized studies are encouraged.
- 1 March 2009
- Published by SAGE Publications in Journal of Endourology
- Vol. 23 (3) , 387-393
Medical Expulsive Therapy as an Adjunct to Improve Shockwave Lithotripsy Outcomes: A Systematic Review and Meta-Analysis
Modern shockwave lithotripsy (SWL) is associated with inferior results compared with the original Dornier HM3. To enhance SWL outcomes, improved patient selection based on radiographic features and modulation of shockwave delivery rate have been used. A growing body of evidence demonstrates the positive effect of medical expulsive therapy (MET) to improve spontaneous passage of urinary calculi. The purpose of this review is to tabulate the current available data that examine the addition of MET to SWL to enhance outcomes. MEDLINE was searched with a strategy developed in conjunction with a medical librarian. Trials were included if patients were randomized to receive either a medical expulsive agent or placebo or standard therapy after SWL. Study quality was assessed according to the Cochrane Renal Group criteria. The data were analyzed using RevMan meta-analysis software. Subgroup analysis was performed with respect to MET agent used, stone size, and duration of follow-up. Four randomized trials were identified. MET agents varied, with two trials using tamsulosin, one using nifedipine, and a single trial using Phyllanthus niruri extract. Two trials included patients with renal calculi, one had patients with ureteral calculi, and the fourth included patients with both ureteral and renal calculi. The pool results of the four trials included 212 patients who received MET and 206 who received placebo. The absolute risk difference of a successful outcome after SWL with the addition of MET was significantly superior to control at 17% (95% confidence interval [CI] 9%-24%); means six patients need to be treated with MET to prevent a single unsuccessful SWL of six (95% CI 4-11). The effect of MET post-SWL was even more pronounced for stones larger than 10 mm with an absolute risk difference of 26% (95% CI, 9%-43%). MET post-SWL results in a significant increase in successful treatment outcomes. Further powered, randomized studies are encouraged.